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ABSTRACT
INTRODUCTION Previous studies have shown that adherence to treatment is 
fundamental to success in smoking cessation. However, smoking cessation 
medication regimens are limited significantly by the struggle to adhere to them. 
This study was conducted to evaluate the factors associated with treatment 
adherence and quitting success in a group of patients that applied to our smoking 
cessation outpatient clinic (SCC). 
METHODS Patients that applied to SCC between April 2015 and December 2016 
who were evaluated, found suitable for smoking cessation interventions and 
started pharmacological treatment were included in this study. Only those who 
could be reached by phone three months after their first application became 
participants. Those who had used the prescribed treatment for at least 30 days 
were grouped as treatment-adherent.
RESULTS In total, data for 346 patients were evaluated. Mean (±SD) age was 
44.3±13.9 years; most of them were male (63%), primary school graduated 
(36.1%), self-employed (43.7%), and had no comorbid diseases (71%). 
Bupropion was started in 52% of the patients, that rate was 35.8% for varenicline 
and 12.1% for a combination of the nicotine patch and gum. Mean days for 
treatment use was 20.9±18.5; 59% of the patients were non-adherent to their 
treatment and 51.7% had only one control visit number. Adverse reactions due to 
treatment were recorded in 25% of participants, and at their third month 37.9% 
of them had quit smoking. In multivariate logistic regression analysis, increase 
in control visit number, absence of adverse reaction, and varenicline use, were 
each associated with higher treatment adherence (p<0.001) and only being in 
the treatment-adherent group was associated with quit success (OR=3.01, 95% 
CI: 1.88–4.81, p=0.001).
CONCLUSIONS This study showed that most patients did not use their prescribed 
SC treatments adequately; a main factor that affects quit success is treatment 
adherence. There is a need for closer monitoring and follow-up to ensure 
adequate use of treatment of patients.
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INTRODUCTION
Smoking is a major cause of preventable early 
deaths worldwide1. Therefore, for a smoker, quitting 
smoking is fundamental to a chance for a longer and 
better life2,3. Most smokers, even at an early age, 
begin to perceive a worsening of their health and 
quality of life4. Most intend or attempt to quit at 
some point in their lives but are not successful5. It 
has been proven that quitting success is higher with 
assistance than without. Furthermore, counseling for 
behavioral therapy plus pharmacotherapy is more 
effective than pharmacotherapy alone6. In the last 
Research Paper
Tobacco Induced Diseases 
Tob. Induc. Dis. 2018;16(August):38
https://doi.org/10.18332/tid/94212     
2
decade, smoking cessation outpatient clinics have 
become active, recommending combination therapy 
for smoking cessation according to guidelines in 
Turkey, the location of the current study. Turkey 
joined the World Health Organization (WHO) 
Framework Convention on Tobacco Control in 
20057. By signing and implementing all of the 
MPOWER policies, overall smoking prevalence 
in Turkey among individuals over 15 years of age 
decreased significantly: from 31.2% in 2008 to 27.1% 
in 20128. Nationwide anti-tobacco policies included 
avoiding secondhand smoke by eliminating smoking 
in all indoor workplaces and public places. Also, the 
number of specified outpatient smoking cessation 
clinics increased in the last decade; until 2002 there 
were 25 in the whole country9. Now, in 2018, that 
number is over 400. Additionally, in 2011 the Turkish 
Ministry of Health (MoH) fist distributed 0.3 million 
varenicline and bupropion drugs to outpatient 
smoking cessation clinics (SCCs), countrywide 
and free of charge10. In 2011, the Turkish MoH 
conducted a program supporting individuals via free 
medications11. A study was conducted to evaluate 
the outcome of that free medication period in the 
first year, 2011; it was reported that willingness and 
adherence to treatment were key points for success in 
smoking cessation. While treatment non-adherence 
is a main factor for the gap between quit success and 
failure, previous studies have also identified non-
adherence to medication as an important predictor of 
smoking relapse12,13 and also for abstinence14.
In randomized clinical trials, adherence to tobacco-
dependence treatments were found12 to be over 98%, 
however that rate is around 25–30% in most real 
life settings13,15. There is one exception: in special 
comorbid groups, such as hospitalised patients for 
myocard infarction, that rate increases16 to 40%.
One of the factors influencing the use of smoking 
cessation medications is their cost, a particular 
barrier for patients with a low socioeconomic 
status13. In 2015 began a second period of free 
distribution of medications. It covered each smoker’s 
cessation medication for 3 months. Our current study 
evaluates the patients who applied in that second 
period. Our reasoning for limiting the study to that 
period was our belief that it is important to evaluate 
the treatment adherence of patients during the free 
period, to evaluate the effect that minimizing the 
cost barrier has. Our aim was to evaluate patients’ 
treatment adherence during the free medication 
period and evaluate their quit status at the end of the 
period. We also wanted to determine and measure 
the effectors for those outcomes. By evaluating quit 
status at the third month, instead of long-term or 
quit status at 12 months, we eliminate other potential 
factors that could affect quitting and relapses outside 
of the free treatment. 
In this study we aimed to assess adherence to 
tobacco dependence treatment during a 3-month free 
varenicline and bupropion distribution period, and 
the factors associated with adherence. A second aim 
was to assess quit status/smoking abstinence status 
at the end of the treatment period, i.e. 3 months after 
beginning the first dose. Our findings will be an 
important reference for identifying gaps in national 
tobacco policies, measuring quantitatively the 
success of free medication periods, and developing 
new implementations for smoking cessation clinics.
METHODS
Setting and participants
The study population consisted of patients who had 
applied to a smoking cessation outpatient clinic located 
in the Eastern Black Sea region of Turkey. This SCC 
had accepted patients one day per week since July 
2014 and was staffed with one pulmonologist who 
was certified and specialized in smoking cessation 
interventions. At the first visit, patients’ medical 
histories, physical examinations, pulmonary function 
tests (PFTs), chest x-rays, and laboratory blood 
analysis were evaluated, and patients were examined 
to determine whether or not they were appropriate 
candidates for smoking cessation interventions. 
The Fagerström test was also administered at this 
time, and not again throughout the rest of the study. 
Collected data regarding patients’ health status were 
recorded on a national electronic database called the 
‘Tobacco Addiction Treatment Follow-up System’. In 
that electronic system, the first line of questioning 
included questions regarding patients’ demographic 
characteristics: age, gender, education level, and job 
title. The other sections covered:  the Fagerström test 
of nicotine addiction level, which was administered 
to all patients at the baseline visit; comorbid diseases 
(through the questions ‘Do you have any other 
disorders? Do you use any medication?’); tobacco 
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use history (‘How long have you been smoking?’); 
number of previous quit attempts and methods used 
(‘How many times you tried to quit, and with which 
method?’); and respiratory system complaints (‘Do 
you have cough, sputum, dyspnea, or wheezing?’). 
Blood pressure was also measured and recorded at 
this time. After recording this needed information, 
brief behavioral interventions based on clinical 
practice guidelines were also provided17 and 
afterwards appropriate treatment was offered to the 
patients, including the prescription of medication, 
if necessary, and setting a quit date. All data were 
recorded by interviewing the pulmonologist and 
patients. 
In April 2015, the Turkish MOH began a second 
free medication period, based on the success of the 
period in 2011. During that time, smoking cessation 
medications (oral bupropion SR and varenicline) 
were distributed to SCCs by the Turkish MoH. 
Patients who started treatment within that period got 
the medications free of charge. They were informed 
about how to use the medication and advised of any 
potential adverse effects, which were also written in 
the patient-signed informed consent form. Then, the 
target quit date (TQD) was decided with patients, 
generally set to be 14 days after that same baseline 
visit. Patients were advised to use the medications 
regularly and to decrease the cigarettes smoked per 
day until the second visit, their TQD. 
At the baseline visit, patients were given 
appointments for a second control visit 14 days 
later. At this second visit, patients were evaluated for 
any drug adverse reactions (‘Do you have any side 
effects due to the medication? What were the side 
effects?’) and asked about their daily smoking habits 
(‘How many cigarettes do you smoke in a day?’); 
abstinence status (‘When did you smoke your last 
cigarette?’); and readiness to quit (‘Are you ready to 
quit smoking today?’). Patients were again provided 
brief behavioral interventions and the next control 
visit date was planned, which was usually 2 weeks 
after this second visit. The same procedures used 
at the second control visit were administered at all 
subsequent visits. Those follow-up visits occurred 
at 2–3 week intervals until enough time had passed 
that all three monthly treatments of the free smoking 
medication could be used. Medication was covered 
for 3 months for each patient in a year.
Inclusion criterias were: 1) Adult smokers (older 
than 18 years old and  ≥10 cigarettes/day over the last 
year and no period of smoking abstinence longer than 
3 months in the past year), 2) being in good general 
health and having no history of bipolar disorder or 
schizophrenia and no current major depression and 
no alcohol abuse, 3) reached by phone calls at their 
third month from the baseline visit. Those who did 
not fall into this category or could not be reached by 
phone at the third month were excluded. 
In total, 395 patients applied to our smoking 
cessation outpatient clinic between 1 April 2015 
and 28 February 2016. Due to comorbid conditions-
schizophrenia (5 patients), current major depression 
(1 patient), history of bipolar disorder (3 patients), 
or alcohol abuse (2 patients)-11 patients did not 
start medication and therefore were excluded from 
the study. After evaluations, 384 were deemed 
suitable for cessation treatment; they were approved 
to quit smoking and prescribed medications. Their 
name, telephone number and identity number were 
recorded from our registry notebook, and other 
demographic data and the control visit information 
were recorded from the electronic tobacco control 
system mentioned above. Three months after their 
first application they were called by phone. In total, 
346 patients (90.1%) were reached; 38 patients 
could not be reached by phone. Based on self-report 
they were grouped as quitters or non-quitters. 
After the baseline visit, patients who had used the 
advised treatment for at least 30 days were grouped 
as treatment-adherent, and the rest were grouped as 
non-adherent.
Before starting the study, ethical approval from 
Artvin Çoruh Universiy Rectorship was obtained, 
also permission for the study was obtained from the 
Hospital’s General Secretary.
Data collection
Sociodemographic characteristics of the patients (age, 
gender, education level, and occupation), comorbid 
diseases, Fagerström test score, treatment choice, 
and number of control visits, were obtained from 
information gathered at the baseline visit for each 
patient and then entered into the mandatory national 
electronic system. From the telephone interviews, 
information regarding the treatments’ effectiveness, 
any adverse reactions and their final smoking 
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situation were evaluated. Final status was recorded 
for 2 categories: 1) quit smoking successfully after 
the planned quit day and still not smoking, and 2) 
could not quit after the planned quit day. Those who 
had quit on the planned quit day but relapsed were 
also classified under the non-quitter category. 
Statistical analysis 
Analysis was done using Statistical Package for 
the Social Sciences, Version 20. We used simple 
descriptive statistics to characterize the study 
population and presented continuous data as 
mean (±SD) and categorical data numerically (%). 
To evaluate the effect of each characteristic (age, 
gender, education level, occupation, Fagerström 
test score, comorbid disease, start date of cessation 
medication, adverse reaction status, and number of 
control visits) on treatment adherence or quit status, 
univariate analysis was performed first. Afterwards, 
all of these variables were analyzed together for any 
possible association or interaction using multivariate 
regression analysis with a Backward LR test. The 
model was found to fit the data for treatment 
adherence: Backward Stepwise (likelihood ratio): 
-2 LOG likelihood: 406.928, Nagelkerke R Square: 
0.220, Omnibus tests of model coefficient: p=0.000, 
Durbin-Watson test: 2.20. It also fit the data for 
quit status: Backward Stepwise (likelihood ratio): 
-2LOG likelihood: 416.276, Nagelkerke R Square: 
0.158, Omnibus tests of model coefficients: p=0.000, 
Durbin-Watson test: 2.20. Results are presented 
as odds ratios and 95% CIs. A p-value < 0.05 was 
considered as significant. 
RESULTS
In total, data for 346 patients were evaluated. Mean 
(±SD) age of participants was 44.3±13.9 years, with 
males the majority (63.9%). Of the participants, 
36.1% had graduated primary school. Detailed 
sociodemographic characteristics of the study 
population are shown in Table 1.
Most of the patients had no comorbid disease 
(71.1%). Mean smoking duration was 22.2±13.1 
years, mean Fagerström test score was 6.6±2.0. Most 
patients were prescribed bupropion (52.0%). Mean 
days of medication use were 20.9±18.5. Most of them 
were non-adherent to their prescribed medication 
(59.0%). Most of them returned for only one follow-
Table 1. Characteristics of the study population, Hopa 
State Hospital, 2015–2016 (n=395 )
Age (Mean±SD) 44.3±13.9  years 
(min 19, max 81)
Gender
Female 125  (36.1%)
Male 221  (63.9%)
Education level
Less than 5 years 5 (1.5%)
5 years primary schooling 125 (36.1%)
3 years secondary schooling 34 (9.8%)
3 years high schooling 114 (32.9%)
University graduated 68 (19.7%)
Occupation
White collar worker 84 (24.3%)
Blue collar worker or farmer 98 (28.3%)
Self employed 52 (43.7%)
Retired 53 (15.3%)
Student 12 (3.5%)
Housewife or not working 86 (24.9%)
Comorbid diseases
Chronic pulmonary or cardiovasculary diseases 68 (19.7%)
Other chronic diseases 32 (9.2%)
No comorbid disease 246 (71.1%)
Smoking duration (mean±SD) 22.2 ± 13.1 years
Fagerström  score 6.6 ± 2.0





Number of days for smoking cessation 
medication use
20.9±18.5 (min 
0,max 90), 0 day 
for 30 (8.7%) 
patients
0 days 30 (8.7%)
≥8 weeks 32 (9.2%)
Treatment adherent 142 (41.0%)
Treatment non-adherent 204 (59.0%)












Quit smoking 131 (37.9%)
Continuing smoking 215 (62.1%)
346 (100%)
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up visit (51.7%), most recorded no adverse reaction 
to prescribed medications (74.6%), and at their third 
month 37.9% had quit smoking (Table 1). Cessation 
was evaluated after a 3-month period, as opposed to 
the traditional at 12 months, for complete cessation, 
because the Turkish government no longer provides 
medications for cessation after that time.
Table 2 shows the relationship between each factor 
and treatment adherence. Bupropion and varenicline 
use were positively associated with treatment 
adherence compared to NRT, both in univariate and 
multivariate analysis. Also, varenicline use was 2.19 
times more associated with treatment adherence 
compared to bupropion as a reference group in 
multivariate analysis. Absence of adverse reactions 
was positively associated with treatment adherence 
in both univariate and multivariate analysis, and 
higher visit numbers were positively associated with 
treatment adherence.
Both middle aged and elderly groups had 
higher association with quitting success compared 
to younger groups in univariate analysis, while in 
multivariate analysis only the rates of middle-aged 
groups were statistically significantly higher than 
for young groups. Increased control visit numbers 
were positively associated with quitting success only 
in univariate analysis. Treatment adherence was 
positively associated with quitting success both in 
univariate and multivariate analyses (Table 3). 
Mean days of prescribed medication use was 
lower in the non-quitter group than quitter group 
(16.2±16.3 vs 28.5±19.3, p=0.001). The most 
common adverse reactions were nausea (30 patients), 
dizziness (12 patients) and dry mouth (11 patients).
Table 2. Factors associated with treatment adherence in univariate and multivariate analyses, Hopa State 
Hospital, 2015–2016 (n=395 )
Backward Stepwise (likelihood ratio): -2 LOG likelihood: 406.928. Nagelkerke R Square: 0.220. Omnibus tests of model coefficient: p=0.000. Durbin-Watson test: 1.96
Univariate analysis Multivariate analysis (Backward: LR)
OR 95% CI p OR 95% CI p
Age group (years)                         
15–44 1
– – NS45–64 1.365 0.647–2.881 0.414
≥65 1.437 0.670–3.082 0.351
Gender (woman compared to man)                          1.251 0.798–1.961 0.328 – – NS
Education level (per 1 level increase) 1.070 0.891–1.285 0.470 – –
Occupation (working actively compared 
to not working)
0.951 0.618–1.465 0.821 – – NS
Fagerström test score (per 1 score 
increase)
0.929 0.832–1.038 0.195 – –
Comorbid disease (presence compared 
to absence)
1.187 0.741– 1.889 0.476 – – NS
Started treatment choice
cNRT 1 1
Bupropion                                                                         3.908 1.566–9.753 0.003 5.185 1.929–13.935 0.001
Varenicline 6.610 2.599–16.810 0.001 8.987 3.258–24.787 0.001
Started treatment choice
Bupropion 1
Not adjusted in multivariate analysiscNRT                                                                                                                                       0.25 0.103–0.639 0.003
Varenicline 1.69 1.065–2.685 0.026
Adverse reaction (absence compared to 
presence)
2.091 1.238–3.532 0.006 3.326 1.868–5.924 0.001
Control visit number (per 1 visit increase) 1.599 1.283–1.993 0.001 1.708 1.353–2.156 0.001
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DISCUSSION
This study shows that most of the patients were non-
adherent to their prescribed medications, did not 
follow their control visits appropriately, and at the 
third month had a quit rate of 37.9%. Varenicline 
and bupropion use had positive associations with 
treatment adherence, while cNRT use had negative 
association. Additionally, varenicline use had 
significantly higher association with treatment 
adherence than either bupropion or cNRT. Absence 
of adverse reactions and increased office visits were 
also positively associated with treatment adherence. 
Older age, increased office visits, and treatment 
adherence were in turn positively associated with 
quit success.
These findings indicate that for successful 
outcomes of smoking cessation interventions, 
patients’ adherence to cessation programs plays 
the key role. Therefore, addressing and discussing 
the factors affecting adherence is of fundamental 
importance to improving smoking cessation 
programs. While there is no standardized description 
of treatment adherence for SC interventions in the 
literature18, in previous studies it has usually been 
classified according to duration of medication use 
or follow-up group therapies19,20, as we did in our 
study. There is a need for a standardized description 
that includes duration of medication use as well as 
status of follow-up visits. While guidelines advise 
for at least 8 weeks of treatment17,21, in our study we 
used a 30-day cut-off period to determine treatment 
adherence; the distributed medications were 
packaged monthly and we asked each participant 
to finish an entire pack. Our results showed that 
our patients’ mean medication use was 20.9±18.5 
days; 59% used it for under 30 days (classified as 
non-adherent to treatment), 8.7% never used the 
advised treatment, and only 32 patients (9.2%) used 
the medication for 8 weeks and over. A single-center 
study that evaluated the effectiveness of smoking 
cessation interventions in 2011, during the first free 
medication period in Turkey, found that 3.95% of 
the patients that were prescribed SC medication 
never used it20. The view was that the smokers 
Table 3. Factors associated with successfull quit attempt in univariate and multivariate analyses, Hopa State 
Hospital, 2015–2016 (n=395 )
Backward Stepwise (likelihood ratio): -2LOG likelihood: 416.276. Nagelkerke R. Square: 0.158. Omnibus tests of model coefficients: p=0.000. Durbin-Watson test: 2.20
Univariate analysis Multivariate analysis (Backward: LR)
OR 95% CI p OR 95% CI p
Age group (years)                         
15–44 1 1
45–64 2.645 1.239–5.647 0.012 2.700 1.221–5.971 0.014
≥65 2.202 1.019–4.759 0.045 2.138 0.956–4.784 0.064
Gender (woman compared to man)                          1.195 0.758–1.885 0.443 – – NS
Education level (per 1 level increase) 0.969 0.805–1.166 0.736 – – NS
Occupation (working actively compared 
to not working)
0.913 0.589–1.414 0.683 – – NS
Fagerström test score (per 1 score 
increase)
0.894 0.552– 1.448 0.649 – – NS
Comorbid disease (presence compared 
to absence)
1.065 0.953–1.190 0.264 – – NS
Started treatment choice
cNRT 1
– – NSBupropion                                                                         1.143 0.571–2.288 0.706
Varenicline 0.852 0.416–1.746 0.662
Adverse reaction (absence compared to 
presence)
0.980 0.594–1.614 0.936 – – NS
Control visit number (per 1 visit increase) 1.305 1.067–1.596 0.009 – – NS
Treatment adherent (adherent compared 
to  non-adherent)
1.599 1.283–1.993 0.001 3.231 2.036–5.129 0.001
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were neither willing nor ready to quit. This is also 
a possible explanation for the current study, which 
also took place during a free medication period. 
Some of the patients most likely just rushed to get 
free medication, because the period is generally only 
a year or a year and a half. Clinician evaluations for 
intentions and stage of motivation for quitting would 
be helpful so that patient education is more effective. 
Another suggestion is a government policy that 
would require covering SC medications under health 
insurance, thus allowing smokers to be able to apply 
whenever they feel ready to quit. 
In 2011, during the first period of free medication 
(varenicline and bupropion SR) distribution in 
Turkey, a nationwide study was conducted to evaluate 
participant outcomes after twelve months in the 
Nationwide Smoking Cessation Treatment Support 
Program11. In that study, researchers evaluated the 
factors affecting quitting and abstinence success. 
Overall quit rate was 27.9% in their study, with higher 
quit rates among varenicline users. In our study, we 
evaluated patients at their third month and found 
the quit rate to be 37.9%. In other national studies, 
the quit rate in the short-term was found to be 25% 
on average20,22. However, in international studies 
that rate was found to be higher23,24 or similar25. In 
our SCC, the same pulmonologist always gave the 
counselling and follow-ups; additionally, there were 
patients that applied after the implementation of 
5A and 5R procedures26 by the same doctor. Such 
factors could possibly contribute to this study 
having a higher quit rate than other national studies. 
However, the limited number of close follow-ups 
and phone contacts, as well as limited extended pre-
treatment and patient education, may explain the 
lower rates than in international studies27. If that 
were the case, more effort and staff are needed for a 
better outcome in Turkey.
Varenicline users’ quit rate was not statistically 
significantly different from the other treatment 
choices, both in univariate and multivariate analyses in 
our study. However, varenicline’s effect on treatment 
adherence was higher than that of bupropion SR 
and cNRT in both analyses. Also, the bupropion SR 
group’s treatment adherence was higher than for 
cNRT. In a review28, combination NRT adherence 
was found to be higher compared to other drugs. 
However, when offered over-the-counter, NRT was 
found to have lower efficacy compared to varenicline 
and bupropion due to premature discontinuation13. 
Most of the reasons for premature discontinuation 
fall into the following categories: relapsing back to 
smoking, experiencing side effects, believing that 
the medication was no longer needed, and wanting 
to avoid the cost13. In our clinical experience, our 
patients have also mentioned those types of reaction; 
however in this study we did not record such 
complaints. In our study, cNRT’s low adherence 
rate can also be explained by the coverage status—
nicotine patches and gums might be difficult for 
smokers to afford. These barriers decrease treatment 
adherence, therefore the government’s policy of 
free application should include all forms of FDA-
approved SC medications. Other reasons for early 
discontinuation should also be evaluated in order to 
find solutions. 
Among patient characteristics, age was found to 
be one of the factors for quit success in our study. 
Older ages were associated with higher quit success, 
even if they did not use adequate amounts of the 
medications. This result is in accordance with 
previous studies that found older adults to have a 
higher quit rate5,29.  
In other national studies, Benli et al.20, for example, 
found that ‘side effects’ were the most common 
reason for early discontinuation. In our study, factors 
that affected treatment adherence were the presence 
of adverse reactions and the number of follow-up 
visits. Absence of adverse reactions was positively 
associated with treatment adherence. Mostly minor 
side effects were reported; among them nausea had 
the highest rate. Overall rate of patients with adverse 
reactions was 25.9%. We believe that overcoming 
adverse reactions would be possible with regular 
visits and patient education. Therefore, more close 
follow-ups, even by phone, are required. There 
is a free national quit-line called ‘ALO 171’ in 
Turkey. Smokers are able to reach out when they 
need assistance, through that quit-line they can also 
arrange their SCC appointments and get counselling. 
Patients using the quit-line are called by phone, first 
at the planned quit date; then after 1 week, 1 month, 
3 months, 6 months, and 12 months, all counted from 
the planned quit date. That call is intended to provide 
motivational support, however our opinion is that 
each SCC should also have a team consisting of staff, 
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familiar to the patients, who can give individualized 
phone support. That level of support would be more 
effective. Before starting treatment, patients should 
also be educated, not only about the side effects of 
the drugs but also about the mechanisms and how 
they will work during the cessation process. The 
benefit of that kind of intervention has been studied 
previously29. Therefore, there is a need for both a 
more professional follow-up team and longer periods 
of cessation efforts.
Lower treatment use is the main problem, and 
factors that affect this result should be evaluated 
and studied to find solutions that will be clinically 
relevant. Also, great care should be taken to choose 
only patients with a sincere intention to quit, and 
only they should be treated for SC. The others, who 
are not ready and are only applying to get the drug 
for use at another time should be educated and 
persuaded to apply when they are ready. On this 
issue, government policy on tobacco addiction plays 
an important role. Because medications were again 
distributed for free for only short periods of time, 
smokers rushed to get the medication, even though 
they did not plan to quit but just to have them for 
future use. At admission, 60 tablets of medication 
were given to patients—enough for 1 month. That 
is one of the reasons our study chose 30 days as the 
cut-off period for treatment adherence. As seen in 
our results, 30 patients had not even started using 
medication by that time. Mean medication use is 
under 30 days and more than half of the patients 
came to follow-up visits only once. Our suggestion 
is that weekly packaging and distribution of drugs 
will be an effective way to increase follow-up visits. 
Patients may be more willing to attend control visits 
in order to receive their medications.  Instead of 
monthly packs, weekly packs allow the doctor to 
prescribe an adequate amount of medicine until 
the planned control visit date. Also, governments 
that offer free medication coverage should include 
all forms of FDA-approved SC medications, not just 
periodically but also regularly. Additionally, Turkey 
has a need for comparison studies between both 
period outcomes.
The study design—the real-life clinical experience 
of patients who underwent smoking cessation 
interventions by the same clinician—makes the 
study strong. However, we did not use any biological 
confirmation of smoking status, instead grouping 
patients according to their report. This is one of the 
limitations of the study. Also, we did not record the 
patient-related reasons for non-adherence with the 
medications. Cessation in this study was measured 
after three months; it would be valuable for future 
studies to follow up one year after the participant’s 
quit date to evaluate whether or not cessation was 
ultimately successful. 
For a higher quit rate, intention to quit should 
be measured objectively in order to start the SC 
intervention at the best time for the patient. For 
the effect of coverage status, SCMs should also be 
evaluated; there is no comparison study on that 
topic in Turkey. There is also a need for qualitative 
studies to evaluate the reasons for not using 
medications adequately. Similarly, long-term follow-
up experiences are needed to gain more data on quit 
success.
CONCLUSIONS
The current study evaluated treatment adherence 
and quit success of patients admitted to a Turkish 
SCC. The results showed that treatment adherence is 
the main factor in quit success. However, most of the 
patients were non-adherent to their prescribed SC 
medications. Additional research and interventions 
such as covering all kinds of approved SCMs, 
changes in packaging and distribution, and closer, 
more individualized follow-ups for motivation and 
support in overcoming minor drug-related side 
effects are required; all of these implementations 
would increase treatment adherence and in turn 
result in a higher quit success. 
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